Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
56,800
+200 (0.35%)
Nov 20, 2025, 3:30 PM KST
0.35%
Market Cap1.20T
Revenue (ttm)20.88B
Net Income (ttm)-8.83B
Shares Out21.16M
EPS (ttm)-675.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume199,486
Average Volume332,499
Open56,600
Previous Close56,600
Day's Range55,000 - 57,600
52-Week Range15,950 - 60,200
Betan/a
RSI71.57
Earnings DateNov 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.